Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum MindBio Therapeutics Corp. C.MBIO

MindBio Therapeutics Corp is a pioneering clinical stage biotechnology company that specializes in developing psychedelic microdosing treatments for mental health conditions. MindBio has obtained government and regulatory approvals for at-home LSD microdosing in clinical trials, making it the only organization in the world to do so.

CSE:MBIO - Post Discussion

View:
Post by Sleepydog24 on May 03, 2024 1:04pm

Nazdaq

If I were Justin I'd approach the same group that took MindMed to the Naz ... they've been very successful very liquid and very much in the investor line of sight always ... this sideways trading for a year now will blow up and re rate in about a week here in the not to distant future ... once this data is out on phase 2 which they have already said is amazing a $50 to $100 mill marketcap is very justifiable and should lead to a senior exchange listing .

SD24
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities